Original Research

Published on 30 Sep 2024

Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events

in Drugs Outcomes Research and Policies

Ben-Nian Huo
Ling Shu
Jian-Wen Xiao
Nan-Ge Yin
Mao-Lin Ai
Yun-Tao Jia
Lin Song

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1292163

1,164 views

Original Research

Published on 26 Sep 2024

Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial

in Drugs Outcomes Research and Policies

Maojin You
Qiaoyan Zheng
Ying He

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1412292

723 views

Original Research

Published on 26 Sep 2024

Gaucher disease in Brazil: a comprehensive 16 year retrospective study on survival, cost, and treatment insights

in Drugs Outcomes Research and Policies

Marcus Carvalho Borin
Juliana Alvares-Teodoro
Francisco Assis Acurcio
Augusto Afonso Guerra

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1433970

604 views

Original Research

Published on 25 Sep 2024

The dose of remimazolam combined with sufentanil for the induction of general anesthesia in obese patients undergoing bariatric surgery: an up-and-down sequential allocation trial

in Drugs Outcomes Research and Policies

Minghui Chen
Huiying Wang
Jiajun Sun
Tao Zhang
Xiaoyin Niu
Tingting Zhang
Jian Liu
Xuan Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1411856

579 views

Editorial

Published on 25 Sep 2024

Editorial: Internet pharmacies and the online pharmacy market: trends, perspectives and challenges

in Drugs Outcomes Research and Policies

András Fittler
Norah Othman Abanmy
Anna Serefko
Inayat Ur Rehman
Róbert György Vida

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1489396

447 views

Original Research

Published on 24 Sep 2024

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database

in Drugs Outcomes Research and Policies

Xinnan Chen
Ying Jiang
Haohao Zhu
Man Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1417661

673 views
1 citation

Original Research

Published on 23 Sep 2024

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China

in Drugs Outcomes Research and Policies

Yue Wu
TianChen Yin
GuiLin Jian
Tao Wan
Benhong Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1373333

659 views

Original Research

Published on 20 Sep 2024

Improving the feasibility of deprescribing proton pump inhibitors: GPs’ insights on barriers, facilitators, and strategies

in Drugs Outcomes Research and Policies

Nuša Japelj
Lea Knez
Davorina Petek
Nejc Horvat

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1468750

668 views

Original Research

Published on 19 Sep 2024

The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab

in Drugs Outcomes Research and Policies

F. J. Esplugues
I. Andújar
J. V. Esplugues

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1447324

801 views

Review

Accepted on 17 Sep 2024

Expert Consensus on the Off-Label Use in China of Drugs for Rare Hematologic Diseases (2024 Edition)

in Drugs Outcomes Research and Policies

Bo-xin Zhao
Xuan Zhou
Ping Zheng
Bo Zhang
Xiaoqin Feng
Jie Chen
Lisheng Cai
Yilu Chen
Liya He
Jianfen Su

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1477550

Original Research

Published on 16 Sep 2024

The approach of Norm Balance in predicting pharmacists’ intention to collaborate with physicians to improve medication therapy

in Drugs Outcomes Research and Policies

Yifei Liu
Karen B. Farris
Dhananjay Nayakankuppam
Bernard A. Sorofman
Julie M. Urmie
William R. Doucette

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1375529

484 views

Original Research

Published on 13 Sep 2024

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

in Drugs Outcomes Research and Policies

Yunhe Fan
Teng Wu
Pengyang Xu
Chuanli Yang
Jie An
Haijia Zhang
Mureed Abbas
Xiushan Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1425171

784 views

Original Research

Published on 13 Sep 2024

The impact of a multidisciplinary team intervention on medication prescription in nursing homes in Catalonia

in Drugs Outcomes Research and Policies

Emilie Anderssen-Nordahl
Eladio Fernández-Liz
Mònica Sabaté Gallego
Montserrat Bosch Ferrer
Margarita Sánchez-Arcilla Rosanas
Mercè Cervera León
Joaquim Miquel Magrinyà
Maria Estrella Barceló-Colomer

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1445141

711 views

Clinical Trial

Published on 12 Sep 2024

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling

in Drugs Outcomes Research and Policies

Kun Zhang
Shanshan Zhao
Jialin Du
Lan Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1474868

569 views

Original Research

Published on 11 Sep 2024

Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study

in Drugs Outcomes Research and Policies

Xiaosheng Zhu
Huai Huang
Mengjie Zou
Honglin Luo
Tianqi Liu
Shaoliang Zhu
Bin Ye

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1442723

1,041 views

Original Research

Published on 04 Sep 2024

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China

in Drugs Outcomes Research and Policies

Zuojuan Xiang
Ling Ma
Yingzhou Fu
Yong Pan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1411571

710 views

Navigation group

Articles

Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events

Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial

Gaucher disease in Brazil: a comprehensive 16 year retrospective study on survival, cost, and treatment insights

The dose of remimazolam combined with sufentanil for the induction of general anesthesia in obese patients undergoing bariatric surgery: an up-and-down sequential allocation trial

Editorial: Internet pharmacies and the online pharmacy market: trends, perspectives and challenges

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China

Improving the feasibility of deprescribing proton pump inhibitors: GPs’ insights on barriers, facilitators, and strategies

The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab

Expert Consensus on the Off-Label Use in China of Drugs for Rare Hematologic Diseases (2024 Edition)

The approach of Norm Balance in predicting pharmacists’ intention to collaborate with physicians to improve medication therapy

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

The impact of a multidisciplinary team intervention on medication prescription in nursing homes in Catalonia

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling

Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China